



14 August 2020

Sydney, Australia

Noxopharm Extraordinary General Meeting Results

Sydney, 14 August 2020: Noxopharm Limited (ASX: NOX), announces the results of today's Extraordinary General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of a poll.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.

Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body's immune system to inflict damage on cancer cells in the body and has shown promise in treating a broad spectrum of cancers.

Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR).

To learn more please visit: <https://www.noxopharm.com/>

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries

Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699



David Franks, Company Secretary of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Disclosure of Proxy Votes

NOXOPHARM LIMITED

Extraordinary General Meeting

Friday, 14 August 2020



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Subsequent approval of prior issue of Shares	P	69,679,757	69,277,071 99.42%	59,062 0.08%	180,000	343,624 0.49%	76,507,857 99.92%	59,062 0.08%	180,000
2 Subsequent approval of prior issue of Unlisted Options	P	69,859,757	69,277,071 99.17%	239,062 0.34%	0	343,624 0.49%	76,507,857 99.69%	239,062 0.31%	0
3 Subsequent approval of prior issue of Shares	P	69,679,757	69,277,071 99.42%	59,062 0.08%	180,000	343,624 0.49%	76,507,857 99.92%	59,062 0.08%	180,000
4 Approval of issue of Underwriter Options	P	63,119,257	62,526,531 99.06%	239,062 0.38%	58,500	353,664 0.56%	69,767,357 99.66%	239,062 0.34%	58,500

